SAMIK PHARM. CO.,LTD.
Founded in 1980 and KOSDAQ-listed in 2025, Samik Pharm manufactures synthetic-drug prescription medicines for cardiovascular and diabetes treatment and operates a CMO business.
As of 2026-10-11, SAMIK PHARM. CO.,LTD. has 191 Korean MFDS drug approvals on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureSamik Pharm was founded in July 1980 and listed on KOSDAQ in October 2025 as a prescription drug manufacturer. It produces synthetic-drug based prescription medicines such as the cardiovascular agents Sezar Tab, Cadenza Tab, S-ol Tab, and Cregi Tab, and the diabetes agents Pioseeta, Januxmax, and Diaglu, alongside OTC products like motion-sickness remedies and cold medicine, while also operating a CMO business. As of end-2025 it handled 117 products, with cardiovascular agents accounting for 46.8% of sales, diabetes agents 10.7%, and CMO 11.4%, trading 32 items with 44 clients in the CMO segment.
Products & technology
- Sezar TabCardiovascular agent (hypertension/hyperlipidemia treatment)
- Cadenza TabCardiovascular agent (hypertension/hyperlipidemia treatment)
- S-ol TabCardiovascular agent (hypertension/hyperlipidemia treatment)
- Cregi TabCardiovascular agent (hypertension/hyperlipidemia treatment)
- PioseetaDiabetes agent (blood glucose control)
- JanuxmaxDiabetes agent (blood glucose control)
- DiagluDiabetes agent (blood glucose control)
- Metformin HClOral hypoglycemic agent for type 2 diabetes (CMO large-scale production)
Regulatory approvals
data.go.kr191 Korean MFDS drug approvals · 1977–2026
- MFDS drugCrezi Tab. 2.5mg2026-06-26Drug · Prescription · Approval202601815
- MFDS drugV-CAB Tab. 20mg2026-01-27Drug · Prescription · Approval202600222
- MFDS drugV-CAB Tab. 10mg2026-01-27Drug · Prescription · Approval202600223
- MFDS drugGinkgostar Tab. 240mg2024-11-08Drug · OTC · Notification202402643
- MFDS drugJanumaxM Tab. 50/850mg2024-02-14Drug · Prescription · Approval202400317
- MFDS drugJanumaxM Tab. 50/500mg2024-02-14Drug · Prescription · Approval202400318
- MFDS drugMaparam Cool Gra.2024-02-08Drug · OTC · Notification202400305
- MFDS drugJanumax Tab. 50mg2024-01-15Drug · Prescription · Approval202400102
- MFDS drugJanumax Tab. 25mg2024-01-15Drug · Prescription · Approval202400103
- MFDS drugPiosita Tab. 100/15mg2023-08-08Drug · Prescription · Approval202302358
- MFDS drugPiosita Tab. 100/30mg2023-08-07Drug · Prescription · Approval202302344
- MFDS drugForxaduo Tab. 10/100mg2023-06-27Drug · Prescription · Approval202301959
Show 68 more
- MFDS drugDipaglu-M XR Tab. 10/1000mg2023-01-17Drug · Prescription · Approval202300275
- MFDS drugDipaglu Tab. 5mg2022-12-16Drug · Prescription · Approval202204518
- MFDS drugDipaglu Tab. 10mg2022-10-31Drug · Prescription · Approval202203948
- MFDS drugJanumaxM XR Tab. 100/1000mg2022-05-17Drug · Prescription · Approval202202077
- MFDS drugJanumaxM XR Tab. 50/1000mg2022-05-17Drug · Prescription · Approval202202078
- MFDS drugJanumaxM XR Tab. 50/500mg2022-05-17Drug · Prescription · Approval202202079
- MFDS drugJanumaxM Tab. 50/1000mg2022-03-02Drug · Prescription · Approval202200899
- MFDS drugOmes Duo Tab. 20/800mg2021-11-04Drug · Prescription · Approval202107332
- MFDS drugRainbow CR Tab.(Levodroporpizine)Revoked2021-06-30Drug · Prescription · Approval202104976
- MFDS drugEmpory Tab. 25mg(Empagliflozin)Revoked2021-03-05Drug · Prescription · Approval202102082
- MFDS drugEmpory Tab. 10mg(Empagliflozin)Revoked2021-03-05Drug · Prescription · Approval202102083
- MFDS drugBARODOWN TAB, 10mg/20mg2021-02-18Drug · Prescription · Approval202101502
- MFDS drugBARODOWN TAB, 10mg/10mg2021-02-18Drug · Prescription · Approval202101503
- MFDS drugBARODOWN TAB, 10mg/40mgRevoked2021-02-18Drug · Prescription · Approval202101501
- MFDS drugZelpanic Tab. 5mgRevoked2020-09-07Drug · Prescription · Approval202006207
- MFDS drugJanumax Tab. 100mg2020-07-15Drug · Prescription · Approval202005113
- MFDS drugDipaclo Tab. 10mgRevoked2020-06-17Drug · Prescription · Approval202004454
- MFDS drugWimoticon Tab.Revoked2020-03-30Drug · OTC · Notification202002183
- MFDS drugHyden Plus Tab. 160/12.5mg2020-02-18Drug · Prescription · Approval202001108
- MFDS drugHyden Tab. 160mgRevoked2020-02-10Drug · Prescription · Approval202000761
- MFDS drugBiphendyl Tab. 25mgRevoked2019-12-24Drug · Prescription · Approval201908601
- MFDS drugGlitina Tab. 5mgRevoked2019-10-15Drug · Prescription · Approval201907236
- MFDS drugSirica Cap. 300mgRevoked2019-09-26Drug · Prescription · Approval201906840
- MFDS drugBertel Plus Tab. 80/12.5mg2019-09-24Drug · Prescription · Approval201906696
- MFDS drugBertel Plus Tab. 40/12.5mg2019-09-24Drug · Prescription · Approval201906697
- MFDS drugGlitina Duo Tab. 2.5/850mgRevoked2019-09-16Drug · Prescription · Approval201906452
- MFDS drugGlitina Duo Tab. 2.5/500mgRevoked2019-09-16Drug · Prescription · Approval201906453
- MFDS drugGlitina Duo Tab. 2.5/1000mgRevoked2019-09-16Drug · Prescription · Approval201906454
- MFDS drugEscar Tab. 10/40mg2019-09-11Drug · Prescription · Approval201906433
- MFDS drugDirosta Tab. 5/20mgRevoked2019-09-10Drug · Prescription · Approval201906401
- MFDS drugDirosta Tab. 5/10mgRevoked2019-09-10Drug · Prescription · Approval201906402
- MFDS drugVarostatin Tab. 40mg2019-09-05Drug · Prescription · Approval201906327
- MFDS drugMaparam Gra.2019-08-28Drug · OTC · Notification201906113
- MFDS drugElbos Cap.2019-07-29Drug · OTC · Notification201905366
- MFDS drugElixaban Tab. 5mg2019-07-29Drug · Prescription · Approval201905370
- MFDS drugElixaban Tab. 2.5mg2019-07-29Drug · Prescription · Approval201905371
- MFDS drugCavilol Tab. 12.5mg2019-07-25Drug · Prescription · Approval201905306
- MFDS drugGripin Tab.30mg2019-07-22Drug · Prescription · Approval201905085
- MFDS drugSBR Tab.Revoked2019-07-02Drug · Prescription · Approval201904509
- MFDS drugDecartan Tab. 8mg2019-06-18Drug · Prescription · Approval201904229
- MFDS drugDecartan Tab. 16mg2019-06-18Drug · Prescription · Approval201904230
- MFDS drugCetroc Tab. 250mgRevoked2019-05-20Drug · Prescription · Approval201903235
- MFDS drugDurchid HR Tab. 600mg2019-04-29Drug · Prescription · Approval201902754
- MFDS drugEsca Tab. 5/20mg2019-04-11Drug · Prescription · Approval201902221
- MFDS drugEsca Tab. 5/40mg2019-04-11Drug · Prescription · Approval201902222
- MFDS drugNewtod Tab. 50mgRevoked2019-03-29Drug · Prescription · Approval201901932
- MFDS drugEsca HCT Tab. 5/40/12.5mg2019-03-19Drug · Prescription · Approval201901667
- MFDS drugDrabe Tab. 20mg2019-01-31Drug · Prescription · Approval201900772
- MFDS drugDrabe Tab. 10mg2019-01-31Drug · Prescription · Approval201900778
- MFDS drugGichikol Tab.Revoked2019-01-31Drug · Prescription · Notification201900758
- MFDS drugEsca HCT Tab. 10/40/12.5mg2019-01-18Drug · Prescription · Approval201900269
- MFDS drugEsca HCT Tab. 5/20/12.5mg2019-01-18Drug · Prescription · Approval201900270
- MFDS drugDoperin Tab. 10mg2018-12-18Drug · Prescription · Approval201805143
- MFDS drugSovomin Syr.2018-02-28Drug · OTC · Notification201801011
- MFDS drugThe Thid Tab.2018-02-26Drug · Prescription · Approval201800947
- MFDS drugFluvir Cap. 75mg2017-10-18Drug · Prescription · Approval201707506
- MFDS drugAlenas Tab.2017-09-12Drug · Prescription · Approval201707062
- MFDS drugMediroll Tab. 4mg2017-04-28Drug · Prescription · Approval201702259
- MFDS drugEravix Plus Cap.2017-03-30Drug · Prescription · Approval201701528
- MFDS drugGaneu Tab. 300mg2017-02-08Drug · Prescription · Notification201700691
- MFDS drugVersace Tab. 40/5mg2016-11-25Drug · Prescription · Approval201606770
- MFDS drugVersace Tab. 40/10mg2016-11-25Drug · Prescription · Approval201606771
- MFDS drugVersace Tab. 80/5mg2016-11-25Drug · Prescription · Approval201606772
- MFDS drugSolitear Tab. 5mg2016-07-04Drug · Prescription · Approval201604147
- MFDS drugSolitear Tab. 10mgRevoked2016-07-04Drug · Prescription · Approval201604148
- MFDS drugShapran Tab. 100mg2016-05-30Drug · Prescription · Approval201603033
- MFDS drugOmes Tab. 20mg2016-02-16Drug · Prescription · Approval201600875
- MFDS drugOmes Tab. 40mg2015-11-17Drug · Prescription · Approval201507736
Showing the 80 most recent of 191 records.
Clinical trials
data.go.kr33 MFDS clinical trial authorisations · 2012–2026 (Bioequivalence 28 · Phase 1 4 · Phase 2 1)
- Phase 1SICH-2601-12026-07-14
2 trial sites
- Phase 1SICL-2601-12026-07-14
2 trial sites
- BioequivalenceSIED-2501-12025-02-17
1 trial site
- BioequivalenceSIVC-2401-12024-04-18
1 trial site
- BioequivalenceSICT-2211-12023-01-06
2 trial sites
- Bioequivalence레인보우정(레보드로프로피진)2022-09-29
2 trial sites
- Phase 1SIPS-2209-12022-07-25
2 trial sites
- Phase 2SIKD19772022-05-19
3 trial sites
- Bioequivalence후루칸정150밀리그램(플루코나졸)2022-03-02
2 trial sites
- Bioequivalence바로스타틴정40밀리그램(아토르바스타틴칼슘삼수화물)2022-02-14
2 trial sites
- Bioequivalence그리핀정30밀리그램(피오글리타존염산염)2021-10-27
2 trial sites
- Phase 1SIFZ-2110-12021-09-02
2 trial sites
Show 21 more
- Bioequivalence다파글루정10밀리그램(다파글리플로진프로판디올수화물)2021-05-25
2 trial sites
- Bioequivalence다파글루엠서방정10/1000밀리그램2021-04-29
2 trial sites
- Bioequivalence다파글루엠서방정10/1000밀리그램2021-04-29
2 trial sites
- Bioequivalence그리핀정30밀리그램(피오글리타존염산염)2021-01-14
2 trial sites
- Bioequivalence에스카정10/40밀리그램2020-09-04
2 trial sites
- Bioequivalence세클펜정(아세클로페낙)(수출명:CECLOFEN Tab.)2020-08-06
2 trial sites
- Bioequivalence바로스타틴정40밀리그램(아토르바스타틴칼슘삼수화물)2020-07-02
2 trial sites
- Bioequivalence디로바정10mg(암로디핀베실산염)2020-06-24
2 trial sites
- Bioequivalence카덴자정10/160mg2020-06-05
2 trial sites
- Bioequivalence자누맥스엠정50/1000밀리그램2019-11-27
1 trial site
- Bioequivalence자누맥스정(시타글립틴인산염수화물)2019-04-01
1 trial site
- Bioequivalence카덴자정10/160mg2018-04-10
2 trial sites
- Bioequivalence에라빅스정(클로피도그렐황산수소염)2017-05-15
2 trial sites
- Bioequivalence메디롤정4mg(글리메피리드)2016-03-07
2 trial sites
- Bioequivalence이타나졸정(이트라코나졸)2015-11-19
- Bioequivalence메모코드정(콜린알포세레이트)2015-07-07
- Bioequivalence아로카정10/40mg2014-07-22
- Bioequivalence크레지정20mg(로수바스타틴칼슘)2014-03-28
- Bioequivalence세라비정2013-05-27
- Bioequivalence삼익글루엠엑스알정(가칭)2013-01-15
- Bioequivalence에스토정(라푸티딘)2012-07-17
1 trial site
R&D and key agreements
Source: DART corporate disclosureSIST2402 · 본태성 고혈압 · 임상1상 · First combination product of S-amlodipine besylate and losartan potassium (low/high dose) for essential hypertension, developed as a chiral drug switching the comparator amlodipine to S-amlodipine to obtain new isomer NDA status; being developed as a first generic, running 2024.03-2027.11.
SLIM2401 · 자가면역질환(류마티스관절염, 원형탈모증 등) · Applying UniSphero technology to develop an oral JAK-inhibitor autoimmune disease treatment as a biodegradable-polymer-based long-acting (1-month) injectable improved new drug, running 2024.03-2027.03.
SLIM2402 · 항암·면역보조 치료 · Project developing a cancer/immune-adjuvant therapeutic as an improved new drug in long-acting injectable form, applying UniSphero technology.
Patents
KIPRIS · applicant-matchedRegistered · 2026-05 · Application 1020260097011
Registered · 2025-12 · Application 1020250211946
Registered · 2025-02 · Application 1020250023332
Registered · 2025-02 · Application 1020250013800
Published · 2022-04 · Application 1020220052556
Registered · 2021-11 · Application 1020210156739
Published · 2021-03 · Application 1020210042181
Registered · 2020-02 · Application 1020200025382
Registered · 2018-11 · Application 1020180144891
Withdrawn · 2013-10 · Application 1020130121360
Show 5 more patents
Registered · 2006-06 · Application 1020060054392
Expired · 2005-10 · Application 1020050093042
Rejected · 1994-06 · Application 2019940015462
Expired · 1994-06 · Application 2019940015463
Expired · 1991-06 · Application 2019910009684
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot75
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 26, 2026 · 5 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for SAMIK PHARM. CO.,LTD. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition